It potentially has involvement in tumour progression, having been shown to promote metastasis formation in vivo and stimulate tumor cell motility, invasiveness, and adhesiveness in vitro. ASAP1 represents a potential target for cancer therapy.
| Inventor | Institute |
|---|---|
| Jonathan Sleeman | Karlsruhe Institute of Technology |
| Cat. #: | 151767 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Cell signaling and signal transduction |
| Application: | IHC ; WB ; ELISA ; IHC ; IP ; WB |
| Target: | ASAP1 |
| Reactivity: | Human ; Rat |
| Clone: | 7B12 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | ASAP1 possesses phosphatidylinositol 4,5-biphosphate-dependent GTPase-activating protein activity for ARF1 (ADP ribosylation factor 1) and ARF5 and a lesser activity towards ARF6. It may coordinate membrane trafficking with cell growth or actin cytoskeleton remodeling by binding to both SRC and PIP2. It potentially has involvement in tumour progression, having been shown to promote metastasis formation in vivo and stimulate tumor cell motility, invasiveness, and adhesiveness in vitro. ASAP1 represents a potential target for cancer therapy. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG2b |
| Immunogen: | Recombinant Protein (fragment of human ASAP1 (corresponding nucleotides 977-1532 of KIAA1249) with N-terminal GST tag produced in E.coli strain BL-21) |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | ASAP1 possesses phosphatidylinositol 4,5-biphosphate-dependent GTPase-activating protein activity for ARF1 (ADP ribosylation factor 1) and ARF5 and a lesser activity towards ARF6. It may coordinate membrane trafficking with cell growth or actin cytoskeleton remodeling by binding to both SRC and PIP2. It potentially has involvement in tumour progression, having been shown to promote metastasis formation in vivo and stimulate tumor cell motility, invasiveness, and adhesiveness in vitro. ASAP1 represents a potential target for cancer therapy. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.84 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Mller et al. 2010. Oncogene. 29(16):2393-403. PMID: 20154719. ASAP1 promotes tumor cell motility and invasiveness, stimulates metastasis formation in vivo, and correlates with poor survival in colorectal cancer patients. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.